Although little work has explored the role of AXL inhibition within the context of PTEN status, one study has shown that selective cytotoxic responses are achieved in PTEN-deficient glioblastoma cells when S6K1 inhibitor LY-2779964 is combined with AXL/TAM kinase inhibitor BMS-777607 or TAM kinase KD, suggesting that the combined targeting of S6K1 and TAMs could be a potential strategy for treatment of PTEN-deficient tumors [315]. The gene discussed is RPS6KB1; the disease is glioblastoma.